1,236 results match your criteria American journal of cancer research[Journal]


Decision making in precision oncology: an issue of mutational contextuality.

Am J Cancer Res 2019 1;9(3):628-629. Epub 2019 Mar 1.

Translational Oncology Laboratory, Avera Cancer Institute Sioux Falls, SD, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448054PMC
March 2019
1 Read

Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients.

Am J Cancer Res 2019 1;9(3):619-627. Epub 2019 Mar 1.

Thoracic Surgery, Sichuan Academy Medical Sciences and Sichuan Provincial People's Hospital Chengdu, P. R. China.

EGFR-TKI had become the first-line treatment of metastatic NSCLC and widely used in clinical. It was reported that there was difference in response rate between NSCLC patients with or without EGFR mutation. However, there was no relevant studies about the difference in clinical response among patients with different kinds of EGFR mutation. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448055PMC
March 2019
6 Reads

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.

Am J Cancer Res 2019 1;9(3):608-618. Epub 2019 Mar 1.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are promising targeted therapeutics for breast and ovarian cancers bearing a germline mutation (), and several have already received regulatory approval in the United States. In patients with a cancer, PARPi can increase the burden of unrepaired DNA double-strand breaks by blocking PARP activity and trapping PARP1 onto damaged DNA. Resistance to PARP inhibitors can block the formation of DNA double-strand breaks through BRCA-related DNA repair pathway. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448061PMC

The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.

Am J Cancer Res 2019 1;9(3):597-607. Epub 2019 Mar 1.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul 05505, Republic of Korea.

Previous studies have shown that transglutaminase 2 (TG2) induces epithelial to mesenchymal transition (EMT) in various tumors. Several studies have also demonstrated the critical role of microRNAs (miRNAs) in regulating EMT of various types of tumors. However, the relationship between TG2 and miRNAs is not well understood. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448065PMC
March 2019
3.968 Impact Factor

Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5.

Am J Cancer Res 2019 1;9(3):585-596. Epub 2019 Mar 1.

Department of Breast and Thyroid Surgery, Changhai Hospital, The Naval Military Medical University Shanghai 200433, China.

Non-coding RNAs (ncRNAs) have been shown to regulate gene expression involved in tumor progression of multiple malignancies. Numerous studies have indicated that N-acetylglucosaminyltransferase V (MGAT5), is an important tumorigenesis and metastasis-associated enzyme in breast cancer (BC). But, the underlying molecular mechanisms by which ncRNAs modulate MGAT5 expression in BC remain undetermined. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448066PMC

Chidamide, a novel histone deacetylase inhibitor, inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A.

Am J Cancer Res 2019 1;9(3):574-584. Epub 2019 Mar 1.

Department of Hematology, Zhongshan Hospital, Fudan University 180 Fenglin Road, Shanghai 200032, China.

Most patients with multiple myeloma (MM) would finally relapse despite the fact that initial MM may turn to remission by conventional chemotherapy. Current chemotherapy regimens have limited effect on relapse MM patients. As a new histone deacetylase inhibitor, chidamide has been used in malignancy treatment. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448057PMC
March 2019
2 Reads

Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models.

Am J Cancer Res 2019 1;9(3):562-573. Epub 2019 Mar 1.

Department of Radiology, Feinberg School of Medicine, Northwestern University Chicago 60611, IL, USA.

Pancreatic ductal adenocarcinoma (PDAC) carries the worst prognosis and caused one of the highest cancer-related mortalities. Dendritic cell (DC) vaccination is a promising cancer immunotherapy; however, the clinical outcomes are often poor. The administration route of DC vaccine can significantly alter the anti-tumor immune response. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448058PMC
March 2019
1 Read

Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Am J Cancer Res 2019 1;9(3):546-561. Epub 2019 Mar 1.

Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University Nanjing 210008, Jiangsu, China.

Sphingosine kinase 2 (SPHK2) is a key factor within sphingolipid metabolism, responsible for the conversion of pro-apoptotic sphingosine to the pro-survival sphingosine-1-phosphate. We have previously shown that ABC294640, a first-in-class SPHK2 inhibitor, inhibits growth of cholangiocarcinoma cells. In a Phase I study of ABC294640 in tumors, the best response was achieved in a cholangiocarcinoma patient. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448062PMC
March 2019
5 Reads
3.968 Impact Factor

Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model.

Am J Cancer Res 2019 1;9(3):529-545. Epub 2019 Mar 1.

Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University NO. 58 Zhongshan Road 2, Guangzhou 510080, China.

Hypoxia plays an extensive role in the development of the tumor microenvironment (TME), particularly in mediating immunosuppression. Respiratory hyperoxia therapy has the potential to improve the effects of conventional cancer therapies via molecular mechanisms mediating antitumor immunity. Here, we investigated whether hyperoxia therapy can restore tumor immunity and inhibit lung metastases in a mouse model of triple-negative breast cancer (TNBC) by treating a 4T1 mammary carcinoma mouse model with normoxia (21% oxygen) or hyperoxia (60% oxygen) therapy, after tumor development. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448063PMC
March 2019
2 Reads
3.968 Impact Factor

Nuclear factor-erythroid 2-related factor 3 (NRF3) is low expressed in colorectal cancer and its down-regulation promotes colorectal cancer malignance through activating EGFR and p38/MAPK.

Am J Cancer Res 2019 1;9(3):511-528. Epub 2019 Mar 1.

Department of Clinical Laboratory, Zhuhai Hospital, Jinan University Zhuhai 519000, Guangdong, China.

Nuclear factor-erythroid 2-related factor 3 (NRF3), a nuclear transcription factor, has been implicated in various cellular processes including carcinogenesis. However, mechanisms underlying its regulation in carcinogenesis are unclear. Herein, we found that NRF3 is lowly expressed in colorectal cancer (CRC) tissues and cells, and NRF3 low-expressions in CRC tissue samples are associated with CRC carcinogenesis and poor patient outcomes. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448064PMC
March 2019
1 Read

The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth.

Am J Cancer Res 2019 1;9(3):496-510. Epub 2019 Mar 1.

Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Jiangsu University Zhenjiang 212001, Jiangsu Province, China.

Emerging evidence indicates that the long noncoding RNA UCA1 is upregulated in multiple cancers, including pancreatic ductal adenocarcinoma (PDAC), and plays a critical role in various complex biological processes. However, the functional roles of UCA1 in PDAC remain to be clarified. In the current study, we showed that UCA1 significantly promoted cell proliferation and tumor growth both in vitro and in vivo, and enhanced stemness maintenance of PDAC cell lines. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448060PMC
March 2019
1 Read

Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma.

Am J Cancer Res 2019 1;9(3):479-495. Epub 2019 Mar 1.

Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University Guangzhou 510080, P. R. China.

Nasopharyngeal carcinoma (NPC), arising from the nasopharynx epithelium, is prevalent among South and East Asia. The radiotherapy is the primary treatment for NPC patients. However, the acquired radioresistance dramatically diminishes the therapeutic effect of radiotherapy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448059PMC
March 2019
2 Reads

Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases.

Am J Cancer Res 2019 1;9(3):459-478. Epub 2019 Mar 1.

Department of Rehabilitation Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu 610041, China.

Triple negative breast cancer (TNBC) patients have a high risk of brain metastases. This deadly disease represents a major challenge for successful treatment, in part because of the poor ability of drugs to penetrate the blood-brain barrier. Antipsychotic drugs show good bioavailability in the brain, and some of them have exhibited anticancer effects in several cancer types. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448056PMC
March 2019
1 Read

CSF-1R regulates non-small cell lung cancer cells dissemination through Wnt3a signaling [Retraction].

Authors:

Am J Cancer Res 2019 1;9(2):458. Epub 2019 Feb 1.

[This retracts the article on p. 2144 in vol. 7, PMID: 29218239. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405978PMC
February 2019
1 Read

Erratum: Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma.

Am J Cancer Res 2019 1;9(2):455-457. Epub 2019 Feb 1.

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine Shanghai 200011, China.

[This corrects the article on p. 999 in vol. 7, PMID: 28469971. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405977PMC
February 2019
1 Read

SHEDding light on the role of Pragmin pseudo-kinases in cancer.

Am J Cancer Res 2019 1;9(2):449-454. Epub 2019 Feb 1.

CBS, CNRS, INSERM, University Montpellier F34090 Montpellier, France.

The human kinome comprises more than 50 pseudo-kinases with unclear biological function due to the absence of apparent catalytic activity, and therefore, with presumably little interest for cancer drug discovery. However, it is now acknowledged that several of them, such as Pragmin family members, play roles as important as those of active kinases in human cancer. How these pseudo-kinases promote tumor formation is largely unknown. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405979PMC
February 2019

Combining peptide TNIIIA2 with all- retinoic acid accelerates N-Myc protein degradation and neuronal differentiation in MYCN-amplified neuroblastoma cells.

Am J Cancer Res 2019 1;9(2):434-448. Epub 2019 Feb 1.

Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science Noda, Chiba, Japan.

Neuroblastoma is one of the common solid tumors of childhood. Nearly half of neuroblastoma patients are classified into the high-risk group, and their 5-year event-free survival (EFS) rates remain unsatisfactory in the range of 30-40%. High-risk neuroblastoma is characterized by amplification of the MYCN gene and excessive expression of its protein product, N-Myc. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405964PMC
February 2019
4 Reads

A sex-dimorphic mouse model of esophageal squamous cell carcinoma.

Am J Cancer Res 2019 1;9(2):429-433. Epub 2019 Feb 1.

Department of Cancer Biology and Mayo Clinic Cancer Center, Mayo Clinic 4500 San Pablo Road, Jacksonville, FL 32224, USA.

Sexual dimorphism in the incidence of human esophageal cancer, including both esophageal adenocarcinoma and squamous cell carcinoma, shows male dominancy. However, the mechanisms that underlie sexual dimorphism of esophageal cancer have been understudied in vivo due to the lack of sex-dimorphic mouse models. Here, we developed a sex-dimorphic mouse model of esophageal squamous cell carcinoma (ESCC) using a lower amount of 4-nitroquinoline-1-oxide (4-NQO) and a shorter latency of tumorigenesis compared to the traditional carcinogenesis procedures. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405973PMC
February 2019

Genetic ablation of mammary ducts through foxa1 prevents breast cancer occurrence.

Am J Cancer Res 2019 1;9(2):424-428. Epub 2019 Feb 1.

Department of Cancer Biology, Mayo Clinic 4500 San Pablo Road, Jacksonville, FL 32224, USA.

Risk reducing mastectomy is the only surgical approach for the prevention of breast cancer in women with deleterious genetic mutations or in those deemed to be at extremely high risk. However, up to 10.5% of these women still developed breast cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405962PMC
February 2019

ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma.

Am J Cancer Res 2019 1;9(2):415-423. Epub 2019 Feb 1.

Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo 135-8550, Japan.

Renal cell carcinoma (RCC) has the high mortality rate among urological malignancies. The development of RCC cannot be effectively reduced by molecular targeted therapies based on nutrient deprivation, such as inhibition of tumor angiogenesis. The objective of this study was to identify predictive biomarkers of poor prognosis and therapeutic molecular targets in patients with RCC. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405968PMC
February 2019
1 Read

Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer.

Am J Cancer Res 2019 1;9(2):406-414. Epub 2019 Feb 1.

Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University Chongqing, People's Republic of China.

Previous studies showed that Livin, a member of inhibitors of apoptosis protein (IAP), played an important role in drug and radiation resistance. When the expression of Livin was blocked, the sensitivity to both chemotherapy and radiotherapy was improved in lung cancer cells. A total of 79 patients diagnosed with non-small cell lung cancer (NSCLC) were enrolled into the current study from Jan 2012 to Apr 2016. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405969PMC
February 2019
1 Read

Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53.

Am J Cancer Res 2019 1;9(2):390-405. Epub 2019 Feb 1.

Human BioMolecular Research Institute and ChemRegen, Inc. San Diego, CA 92121, USA.

Pancreatic ductal adenocarcinoma (PDAC), constitutes >90% of pancreatic cancers (PC) and is one of the most aggressive human tumors. Standard chemotherapies for PDAC (e.g. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405982PMC
February 2019

Epithelial ovarian cancer: feasibility of image-guided intratumoral radiofrequency hyperthermia-enhanced direct gene therapy.

Am J Cancer Res 2019 1;9(2):378-389. Epub 2019 Feb 1.

Image-Guided Biomolecular Intervention Research, Section of Interventional Radiology, Department of Radiology, University of Washington School of Medicine Seattle, WA, USA.

The aim of this study was to develop an interventional oncologic technique, "Image-guided intratumoral radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus-thymidine kinase (HSV-TK) gene therapy of ovarian cancer. This study consisted of three portions: (1) serial in-vitro experiments to establish "proof-of-principle" of this novel technique using human ovarian cancer cells; (2) serial in-vivo experiments to validate technical feasibility using animal models with the same orthotopic ovarian cancers; and (3) serial investigations into the underlying bio-molecular mechanisms of this technique. We included four subject groups: (i) combination therapy with RFH+HSV-TK gene therapy; (ii) gene therapy-only; (iii) RFH-only; and (iv) Phosphate-buffered saline (PBS). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405963PMC
February 2019
2 Reads

SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma.

Am J Cancer Res 2019 1;9(2):363-377. Epub 2019 Feb 1.

Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, China.

Secreted Frizzled-Related Protein 4 (SFRP4), a member of secreted frizzled-related protein family, has been found as a vital modulator in cell proliferation, cell self-renew and apoptosis through Wnt signaling transduction pathway. In the present study, we re-analyzed the expression pattern of SFRPs in Gene Expression Omnibus (GEO) datasets and evaluated the expression of SFRP4 at protein level in both Kras; Trp53; Pdx1-Cre; (KPC) mice and human pancreatic ductal adenocarcinoma (PDAC) tissue. We found that the expression of SFRP4 increased gradually in PanINs and PDAC lesions in KPC mice and high expression of SFRP4 was much more common in tumor lesions compared to the adjacent non-tumor tissues. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405984PMC
February 2019
1 Read

DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCR1 axis.

Am J Cancer Res 2019 1;9(2):347-362. Epub 2019 Feb 1.

Department of Anatomy, Faculty of Medicine, Chung Shan Medical University Taichung, Taiwan.

Abnormal expression of dermatan sulfate epimerase (DSE) has been found in many types of cancer, while its expression and biological functions in hepatocellular carcinoma (HCC) progression remains obscure. Here we report that DSE, the enzyme that catalyzes the conversion of chondroitin sulfate (CS) to dermatan sulfate (DS), is a critical mediator of malignant character in HCC, through regulation of CCL5 signaling. DSE mRNA and protein were downregulated frequently in HCC tumors, where these events were associated with advanced tumor stages, metastases, and poor survival. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405965PMC
February 2019

Dickkopf-1 (DKK1) promotes tumor growth via Akt-phosphorylation and independently of Wnt-axis in Barrett's associated esophageal adenocarcinoma.

Am J Cancer Res 2019 1;9(2):330-346. Epub 2019 Feb 1.

Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Germany.

Esophageal adenocarcinoma (EAC) is still associated with poor prognosis, despite modern multi-modal therapies. New molecular markers, which control cell cycle and promote lymph node metastases or tumor growth, may introduce novel target therapies. Dickkopf-1 (DKK1) is a secreted glycoprotein that blocks the oncogenic Wnt/β-catenin signaling and its aberrant expression has been observed in many malignancies, including EAC. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405970PMC
February 2019
2 Reads

MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer.

Am J Cancer Res 2019 1;9(2):312-329. Epub 2019 Feb 1.

Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203, China.

Activated KRAS is frequently observed and paralleled by inactivating of tumor suppressors in lung cancer, while the mechanisms remained elusive. Here, our study revealed a microRNA was involved in KRAS overexpression, activation of KRAS signaling and its synergy with inactivating of tumor suppressor genes. miR-1205 was selected by its sequence-dependent inhibition on KRAS and negative clinical correlation with KRAS. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405972PMC
February 2019
1 Read

Long noncoding RNA CASC11 promotes osteosarcoma metastasis by suppressing degradation of snail mRNA.

Am J Cancer Res 2019 1;9(2):300-311. Epub 2019 Feb 1.

Department of Pulmonary Tumor Surgery, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology Luoyang 471003, Henan Province, China.

Osteosarcoma (OS) is the most common primary bone tumor in adolescents. Dysregulation of long noncoding RNAs (lncRNAs) is associated with the cancer progression, of which cancer susceptibility candidate 11 (CASC11) has been indicated as an oncogene in several human cancers. However, the underlying mechanisms by which CASC11 contributes to OS metastasis remain undetermined. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405980PMC
February 2019

E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation.

Am J Cancer Res 2019 1;9(2):285-299. Epub 2019 Feb 1.

Central Laboratory, Sanmen People's Hospital of Zhejiang Sanmen, China.

For decades, E2F1 has been recognized as a retinoblastoma protein (RB) binding transcription factor that regulates the cell cycle. E2F1 binds preferentially to RB and accelerates the cell cycle in most cancer cells. However, it is thought that E2F1 modulates cell proliferation in other ways as well. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405983PMC
February 2019

The positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates malignancy in non-small cell lung cancer.

Am J Cancer Res 2019 1;9(2):270-284. Epub 2019 Feb 1.

Department of Respiratory, The First Affiliated Hospital of Zhengzhou University China.

Non-small cell lung cancer (NSCLC) is one of the most frequent cancers worldwide. The abnormal expression of long non-coding RNAs (lncRNAs) has been reported to be closely associated with the progression of human cancers, including NSCLC. Here, we demonstrated that differentiation antagonizing noncoding RNA (DANCR) was overexpressed in NSCLC tissues. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405976PMC
February 2019
1 Read

MicroRNA-940 inhibits glioma progression by blocking mitochondrial folate metabolism through targeting of MTHFD2.

Am J Cancer Res 2019 1;9(2):250-269. Epub 2019 Feb 1.

Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University Nanjing, China.

The aggressiveness and recurrence of glioma are major obstacles for the treatment of this type of tumor. Further understanding of the molecular mechanisms of glioma is necessary to improve the efficacy of therapy. MicroRNAs have been widely studied in many human cancers. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405966PMC
February 2019
3.968 Impact Factor

Interplay between heat shock proteins, inflammation and cancer: a potential cancer therapeutic target.

Am J Cancer Res 2019 1;9(2):242-249. Epub 2019 Feb 1.

Biotechnology and Structural Biology (BSB) Group, Department of Biochemistry and Microbiology, University of Zululand KwaDlangezwa 3886, South Africa.

The historical relationship between cancer and inflammation has long been evaluated, and dates back to the early work of Virchow (1863), where he hypothesised that chronic inflammation as a direct cause of tissue injury and infection, could actually promote tissue proliferation. At that period in time however, the exact mechanisms that mediated this relationship were little understood. Subsequent studies have since then demonstrated that chronic inflammation plays significant roles in microenvironments, mostly in the progression of tumours, probably, through over-secretion of proinflammatory cytokines and other immune-killing apparatus such as reactive oxygen species (ROS) which cause damage to normal cells leading to DNA damage and increased cellular mutation rates. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405974PMC
February 2019
2 Reads
3.968 Impact Factor

Target selection of CAR T cell therapy in accordance with the TME for solid tumors.

Am J Cancer Res 2019 1;9(2):228-241. Epub 2019 Feb 1.

Cancer Research Institute, Central South University Changsha, Hunan Province, China.

Chimeric antigen receptor-engineered T (CAR T) cell therapy has made great progress in hematological malignancies and resulted in two newly FDA-approved drugs specific for CD19, and . To some extent, this success is attributable to the appropriately selected antigen, CD19, a cell surface protein that is uniformly and strongly expressed on malignant B cells. This result indicates that a proper CAR target is of great importance to the success of this technique. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405971PMC
February 2019

The role of cholesterol metabolism in cancer.

Am J Cancer Res 2019 1;9(2):219-227. Epub 2019 Feb 1.

Multidisciplinary Center for Pituitary Adenomas of Chongqing, Department of Neurosurgery, Xinqiao Hospital, Army Medical University Chongqing, China.

Cholesterol plays an important role in cancer development. Both clinical and experimental studies have found that hypercholesterolemia and a high-fat high-cholesterol diet can affect cancer development. External cholesterol can directly activate the oncogenic Hedgehog pathway, and internal cholesterol can induce mTORC1 signaling. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405981PMC
February 2019

Compound-therapy based on cancer-immunity cycle: promising prospects for antitumor regimens.

Authors:
Dong Gao

Am J Cancer Res 2019 1;9(2):212-218. Epub 2019 Feb 1.

Research Institute of Shenzhen Beike Biotechnology Co., Ltd. Keyuan Road 18, Shenzhen, Guangdong, P. R. China.

Immunotherapy has made a significant impact on the survival of patients with different tumor. However, it has become clear that they are not sufficiently active durable responses for many tumor patients, but only in a fraction of tumor patients. In order to improve this, combination regimens revealed impressive synergistic effects by combination of doublet or triplet immune agents. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405975PMC
February 2019
2 Reads

The metabolic modulator PGC-1α in cancer.

Am J Cancer Res 2019 1;9(2):198-211. Epub 2019 Feb 1.

Université Nice Côte d'Azur, Inserm, C3M, Centre Méditerranéen de Médecine Moléculaire (INSERM U1065) Nice, France.

The peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) is a central modulator of cell metabolism. It regulates mitochondrial biogenesis and oxidative metabolism. Modifications and adaptations in cellular metabolism are hallmarks of cancer cells, thus, it is not surprising that PGC-1α plays a role in cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405967PMC
February 2019

Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer.

Am J Cancer Res 2019 1;9(1):186-197. Epub 2019 Jan 1.

Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University Guangzhou 510632, China.

Integrin-linked kinase (ILK), which is an ankyrin repeat-containing serine/threonine protein kinase, interacts with integrin β1 and the β3 cytoplasmic domain and phosphorylates integrin β1. ILK has multiple functions in cells, such as cell-extracellular matrix interactions, cell cycle, apoptosis, cell proliferation and cell motility, which are associated with the interacting partners of ILK and downstream signaling pathways. Upregulation of ILK is frequently observed in cancer tissues compared to corresponding normal tissues. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356918PMC
January 2019

An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5.

Am J Cancer Res 2019 1;9(1):180-185. Epub 2019 Jan 1.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center Houston 77030, Texas, USA.

Methylation at Arg198 and Arg200 residues of the EGFR extracellular domain by PRMT1 have been demonstrated to enhance EGFR activation by the canonical ligands, EGF and TGFα. On the other hand, RNase 5 was identified as a new ligand of EGFR recently. However, the interplay between EGFR methylation and RNase 5 in EGFR activation is still unclear. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356926PMC
January 2019

Neural correlates of chemotherapy-induced emotion regulation impairment in breast cancer patients.

Am J Cancer Res 2019 1;9(1):171-179. Epub 2019 Jan 1.

Department of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.

To investigate the chemotherapy-induced emotion regulation impairment and its neural correlates in breast cancer (BC) patients by event-related potentials (ERP), seventeen BC patients were investigated on emotion regulation paradigms while undergoing the recording of an event-related potential (ERP) both before and after chemotherapy. The performance of behavioral and ERP was compared for the data collected before and after chemotherapy (BCB and BCA, respectively). The correlation of the difference between the peak and the latency of each component before and after chemotherapy were compared with the difference in behavior (RT and AR). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356929PMC
January 2019

Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.

Am J Cancer Res 2019 1;9(1):160-170. Epub 2019 Jan 1.

Département de Microbiologie et Infectiologie, Département de Chirurgie, Faculté de Médecine, Université de Sherbrooke 3001, 12ième Avenue Nord, Sherbrooke, J1H 5N4, Canada.

About 20% of patients with high grade serous epithelial ovarian carcinoma (HGSOC) are intrinsically resistant to standard first-line platinum-based combination therapy. There is no marker yet available to identify these patients. In that context, all patients with HGSOC initially receive the same standard first-line platinum-based therapy, and those with intrinsically resistant diseases can only be identified retrospectively after they experienced early relapse to therapy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356915PMC
January 2019
1 Read

Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.

Am J Cancer Res 2019 1;9(1):145-159. Epub 2019 Jan 1.

Department of Pathology and Laboratory Medicine, Medical University of South Carolina Charleston, SC 29425, USA.

The scaffold/adaptor growth factor receptor bound 2 (GRB2)-associated binding protein 2 (GAB2) is frequently amplified and/or overexpressed in primary high-grade serous ovarian cancers (HGSOCs). Here we investigate a novel treatment strategy by targeting SHP2 and PI3K signaling in HGSOCs with GAB2 amplification/overexpression (GAB2). The expression of GAB2 was analyzed in primary HGSOCs and ovarian cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356928PMC
January 2019
1 Read

Dysregulated ENPP1 increases the malignancy of human lung cancer by inducing epithelial-mesenchymal transition phenotypes and stem cell features.

Am J Cancer Res 2019 1;9(1):134-144. Epub 2019 Jan 1.

Key Laboratory of Cell Differentiation and Apoptosis of Chinese Minister of Education, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.

Induction of cancer stem cell (CSC) characters and epithelial mesenchymal transition (EMT) features are crucial in tumor initiation, progression and metastasis. However, underlying mechanisms remain incompletely understood. Here, we showed that ENPP1 plays an important role in inducing and maintaining EMT phenotypes and CSC features in lung cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356920PMC
January 2019

Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment.

Am J Cancer Res 2019 1;9(1):122-133. Epub 2019 Jan 1.

Laboratory of Cell Biology, Bergen County Academies 200 Hackensack Ave, Hackensack, NJ 07601, USA.

Isocitrate dehydrogenases (IDHs) are enzymes involved in the production of α-ketoglutarate (αkg) in normal cellular metabolism. Cells with IDH mutations reduce αkg to 2-hydroxyglutarate (2HG), an oncometabolite, and 2HG directly transforms normal cells to malignant cells through histone demethylation and epigenetic dysregulation. However, whether IDH mutations affect cancer stromal cells is elusive, and little is known whether 2HG may impact the tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356916PMC
January 2019
1 Read

Long noncoding RNA GAS5 inhibits metastasis by targeting miR-182/ANGPTL1 in hepatocellular carcinoma.

Am J Cancer Res 2019 1;9(1):108-121. Epub 2019 Jan 1.

Hepatobiliary Surgery, The First Affiliated Hospital of Jinzhou Medical University Jinzhou 121001, Liaoning Province, China.

Intrahepatic and extrahepatic metastases are responsible for the majority of hepatocellular carcinoma (HCC)-related mortalities. Long noncoding RNAs (lncRNAs) exert important functions in modulating various tumor behaviors. However, the functions and mechanisms of lncRNAs in HCC metastasis remain largely unknown. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356919PMC
January 2019

Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.

Am J Cancer Res 2019 1;9(1):94-107. Epub 2019 Jan 1.

Department of Biological Sciences, Sungkyunkwan University Suwon 16419, Republic of Korea.

Covalent conjugations of the SUMO-1 moiety on a target protein play important roles in the regulation of cellular protein function. SUMO-conjugation of PML is a regulatory step for PML nuclear body (PML-NB) formation, and HIPK2 is SUMO-conjugated and recruited into the PML-NBs. Although HIPK2 mutations (R861W and N951I) were found in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, little is known about the underlying mechanisms by which HIPK2 mutations are associated with the pathogenesis of leukemia. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356924PMC
January 2019
1 Read

A p53-stabilizing agent, CP-31398, induces p21 expression with increased G2/M phase through the YY1 transcription factor in esophageal carcinoma defective of the p53 pathway.

Am J Cancer Res 2019 1;9(1):79-93. Epub 2019 Jan 1.

Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan.

Restoration of p53 functions is one of the therapeutic strategies for esophageal carcinoma which is often defective of the p53 pathway. We examined effects of CP-31398 which potentially increased expression of wild-type p53 or converted mutated p53 to the wild-type. We used 9 kinds of human squamous esophageal carcinoma cells with different genotypes and examined expression of p53 and the related molecules in CP-31398-treated cells. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356922PMC
January 2019
1 Read
3.968 Impact Factor

A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Am J Cancer Res 2019 1;9(1):64-78. Epub 2019 Jan 1.

The Cyrus Tang Hematology Center, Soochow University Suzhou, Jiangsu, P. R. China.

Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a challenge since most target antigens are shared between normal and malignant cells, leading to CAR-T cell fratricide. CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL), but it is not expressed in one small group of normal T lymphocytes. Here, we constructed monovalent CD7-CAR-NK-92MI and bivalent dCD7-CAR-NK-92MI cells using the CD7 nanobody VHH6 sequences from our laboratory. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356925PMC
January 2019
7 Reads

Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.

Am J Cancer Res 2019 1;9(1):53-63. Epub 2019 Jan 1.

Department of Medical Physics, University of Wisconsin-Madison Madison, WI 53705, USA.

Imaging of immunotherapy targets using positron emission tomography (PET) can allow for noninvasive monitoring of their dynamic expression and may allow for patient stratification in the future. Therefore, two tracers targeting CTLA-4, one a full antibody and the other a F(ab') fragment, were radiolabeled with Cu and validated in humanized mouse models. Ipilimumab was digested to develop ipilimumab-F(ab'), and both the intact antibody and the fragment were conjugated with NOTA to chelate Cu for PET. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356917PMC
January 2019

microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targeting and deactivating the Wnt/β-catenin pathway.

Am J Cancer Res 2019 1;9(1):36-52. Epub 2019 Jan 1.

Department of Emergency, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, P. R. China.

microRNAs (miRNAs) are frequently aberrantly expressed in osteosarcoma (OS) and are implicated in its development. Dysregulation of miR-758 has been reported in various human malignancies. However, whether miR-758 is involved in the oncogenesis and progression of OS remains unclear. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356927PMC
January 2019
9 Reads

Overexpressed ACP5 has prognostic value in colorectal cancer and promotes cell proliferation and tumorigenesis via FAK/PI3K/AKT signaling pathway.

Am J Cancer Res 2019 1;9(1):22-35. Epub 2019 Jan 1.

Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai 200127, P. R. China.

The tartrate-resistant acid phosphatase (TRAP/ACP5) correlated with tumor progression in many malignancies. However, the role of ACP5 in colorectal cancer (CRC) has not been thoroughly elucidated. In this study, we sought to identify the role for ACP5 in CRC progression. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356923PMC
January 2019